Tumor tissue will undergo testing for changes in more than 160 genes. If a patient's tumor has a genetic change that matches one targeted by a drug used in the trial, the patient may be eligible to join the treatment arm targeting that genetic change.

FREDERICK, Md. -- The National Cancer Institute–Children’s Oncology Group trial known as Pediatric MATCH (Molecular Analysis for Therapy Choice) trial launched in 2017, with significant operations and technical support from the Frederick National Laboratory for Cancer Research. Focusing on patients aged 1–21, Pediatric MATCH seeks to determine whether precision medicines that are designed to treat specific cancers with certain mutations can also treat other cancers with the same mutations.

NHP Models- Medicine, Simian Immunodeficiency Virus (SIV), Simian/Human Immunodeficiency Virus (SHIV), FNL SHIVs, FNL Barcoded SIV, Analysis, Study Design

FREDERICK, Md. -- Scientists at the Frederick National Laboratory for Cancer Research, the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, and a team of collaborators have filled a gap in HIV research by developing 38 new simian/human immunodeficiency viruses (SHIVs) for prevention and treatment studies. The viruses are available to the scientific community through the national laboratory’s AIDS and Cancer Virus Program (ACVP).

Stock image of blood in a test tube

FREDERICK, Md. – Tissue biopsies are currently the norm for detecting and obtaining information about cancer. But this type of biopsy can be invasive, and not every patient can have one performed due to the location of their tumor or other health factors.   

Chicago skyline

CHICAGO – Frederick National Laboratory researchers will present their work across a range of cancer research topics including genomics, precision medicine, and molecular characterization at the annual meeting of the world’s leading clinical oncology organization.

The 2019 ASCO Annual Meeting in Chicago is expected to bring together more than 32,000 oncology professionals from around the globe. Each year, the conference features leading cancer experts who share the latest clinical cancer research affecting patient care. 

Frederick County Executive Jan Gardner speaks at the 2018 Technology Showcase at the Frederick National Laboratory. Photo by Richard Frederickson, staff photographer.

FREDERICK, Md. -- Next month, the annual Technology Showcase will return to the Frederick National Laboratory for Cancer Research. The event attracts research innovators and business professionals who wish to learn about advanced technologies being developed at the National Cancer Institute (NCI) and Frederick National Laboratory (FNL). 

More than 300 NCI technologies are currently available for licensing or collaboration leading to commercialization. The 2019 Technology Showcase aims to bring more visibility to external researchers for these opportunities at the NCI and FNL. 

Illustration of nanotechnology-based drug products, leukocytes, platelets, and complement.

FREDERICK, Md. -- A new technical service offered by the Frederick National Laboratory for Cancer Research will help researchers screen their nanoformulations for the risk of causing infusion reactions. 

The Imaging Science and Cancer Biology Symposium, June 21-23, 2019

FREDERICK, Md. -- Some of the world’s top experts in imaging and cancer biology will present the latest research in this growing field at the Leidos Biomedical Research and Hood College Imaging Science and Cancer Biology Symposium, June 21–23. Cancer researchers are invited to attend the conference, to be held on the Hood campus in Frederick, Md.

Data cloud sharing illustration. Image by Joseph Meyer, staff illustrator.

FREDERICK, Md. -- For Kedar Narayan, a little-known research tool is helping him meet a critical need in his work at the Frederick National Laboratory for Cancer Research. 

Narayan is a senior scientist and group lead at the Center for Molecular Microscopy. He investigates urgent problems in cancer biology by using emerging technologies to obtain high-resolution images of tissues and cells. He wants the broader cancer research community to access his work, but traditional repositories are not suited for his data type, limiting his ability to share it. 

Larry Arthur (right) recruited HIV/AIDS expert Jeff Lifson to his AIDS Vaccine Program at the Frederick National Laboratory in 1995.

FREDERICK, Md. -- As a deadly mystery disease with an unknown etiology caused worldwide panic in the early 1980s and quickly became an epidemic, Dr. Jeffrey Lifson was right in the middle of it. 

He was a recent medical school graduate and cellular immunology fellow at Stanford Medical School where he saw early cases of what would become known as AIDS.

Jeff Lifson (left) has been director of the AIDS and Cancer Virus program for nearly 20 years. He’s pictured here with colleagues Brandon Keele, Jake Estes and the late Michael Piatak.

A Race Against the Unfolding Epidemic

Published: 3/19/2019Tagged:

FREDERICK, Md. -- In the immunology lab at Stanford Hospital there was a sense of urgency to discover the culprit of the strange disease that caused rare cancers and infections, initially diagnosed among gay men. It was 1983, and the first signs of what would become the AIDS threat were outlined in a series of reports from the Centers for Disease Control and Prevention and publications in the New England Journal of Medicine in 1981.

Pages